Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases. As a leading orphan endocrine disease company, we create distinct and transformative treatments for a wide range of endocrine diseases where there is a significant unmet medical need. We are currently advancing a pipeline that includes the following potentially first-in-class product candidates: Livoletide (AZP-531) for the treatment of Prader-Willi syndrome; Nevanimibe (ATR-101) for the treatment of classic congenital adrenal hyperplasia; MLE-301 for the treatment of vasomotor symptoms (VMS) associated with menopause. Source
No articles found.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers...
At Biogen, our mission is clear: we are pioneer...
HelloAva is an innovative new platform that uses AI technology to provide a person...
HelloAva is an innovative new platform that use...
EyeGate is developing and commercializing products for treating diseases and disor...
EyeGate is developing and commercializing produ...
Vaccinex is a clinical-stage biotechnology company engaged in the discovery and de...
Vaccinex is a clinical-stage biotechnology comp...
Oramed Pharmaceuticals (NASDAQ: ORMP) was established in 2006, and has developed a...
Oramed Pharmaceuticals (NASDAQ: ORMP) was estab...
We discover and develop medicines to defeat neurodegeneration. The science is brea...
We discover and develop medicines to defeat neu...
Aeterna Zentaris is a specialty biopharmaceutical company focused on developing an...
Aeterna Zentaris is a specialty biopharmaceutic...
Join the National Investor Network and get the latest information with your interests in mind.